| __timestamp | CRISPR Therapeutics AG | Celldex Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 1513000 | 101881000 |
| Thursday, January 1, 2015 | 12573000 | 4011000 |
| Friday, January 1, 2016 | 42238000 | 102026000 |
| Sunday, January 1, 2017 | 69800000 | 96171000 |
| Monday, January 1, 2018 | 113773000 | 66449000 |
| Tuesday, January 1, 2019 | 179362000 | 42672000 |
| Wednesday, January 1, 2020 | 269407000 | 42534000 |
| Friday, January 1, 2021 | 17953000 | 3068000 |
| Saturday, January 1, 2022 | 110250000 | 1400000 |
| Sunday, January 1, 2023 | 130250000 | 3008000 |
| Monday, January 1, 2024 | -2314000 |
Infusing magic into the data realm
In the dynamic world of biotechnology, understanding the financial health of companies is crucial. This analysis delves into the cost of revenue trends for CRISPR Therapeutics AG and Celldex Therapeutics, Inc. over the past decade.
From 2014 to 2023, CRISPR Therapeutics AG has seen a remarkable increase in its cost of revenue, peaking in 2020 with a 1,680% rise from its 2014 figures. This growth reflects the company's expanding operations and investment in cutting-edge gene-editing technologies.
Conversely, Celldex Therapeutics, Inc. experienced a more volatile trajectory. After a significant cost in 2014, the company saw fluctuations, with a notable 97% decrease by 2023. This pattern highlights the challenges and strategic shifts within the company.
These insights offer a glimpse into the financial strategies and market positioning of these biotech pioneers.
Analyzing Cost of Revenue: Merck & Co., Inc. and Celldex Therapeutics, Inc.
Cost of Revenue Comparison: Pfizer Inc. vs CRISPR Therapeutics AG
Cost Insights: Breaking Down Regeneron Pharmaceuticals, Inc. and CRISPR Therapeutics AG's Expenses
Comparing Cost of Revenue Efficiency: Intra-Cellular Therapies, Inc. vs Celldex Therapeutics, Inc.
Cost of Revenue Comparison: Grifols, S.A. vs CRISPR Therapeutics AG
Analyzing Cost of Revenue: Ionis Pharmaceuticals, Inc. and Celldex Therapeutics, Inc.
Cost of Revenue Trends: Amneal Pharmaceuticals, Inc. vs Celldex Therapeutics, Inc.
Comparing Cost of Revenue Efficiency: CRISPR Therapeutics AG vs Ligand Pharmaceuticals Incorporated
CRISPR Therapeutics AG vs Amphastar Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: CRISPR Therapeutics AG vs Wave Life Sciences Ltd.
Cost Insights: Breaking Down CRISPR Therapeutics AG and Viridian Therapeutics, Inc.'s Expenses
Cost of Revenue: Key Insights for Vericel Corporation and Celldex Therapeutics, Inc.